Genmab — December 2020

[E_L]

yes, i know it is supposed to come soon, i had hoped a bit just before ASH. But if it is not yet in the clinic, it is pre-clinical in my vocabulary

[E_L]

by the way, i also thought it was funny that Epco takes as much space on that page as Dara, Ofa and Tepezza together lol. How priorities
change

[Bulder]

Epco is the future. Tomorrow is as exciting as Sirius data in the past.

[GeorgeBest]

Talquetamab https://twitter.com/mohty_ebmt/status/1335139956205948929?s=21

[E_L]

yes, Sirius lol, that feels llike 100 years ago...

[Bulder]

It is. 33% ORR, and we all went berserk. Never seen before

[E_L]

lets hope we have a simillar feeling this weekend

[E_L]

this is where i think we will be able to see everything, Materials will be available on a rolling basis as soon as individual embargoes are lifted. Dara has some lifted already https://www.oncologysciencehub.com/ash2020/

[E_L]

well not epco offourse only the JNJ stuff

[E_L]

Updated Phase 1 Results of Teclistamab https://www.oncologysciencehub.com/ash2020/bispecifics/garfall/#slides

[E_L]

wasnt blenrep something like 35% ORR?

[GeorgeBest]

Nina Shah synes om Teclistamab https://twitter.com/ninashah33/status/1335327442563596289?s=21

[GeorgeBest]

Mange lignende kommentarer på Twitter, alle positive og „big advantage compared to CAR-T“

[peter12]

ORR er da tæt på 100% ved RP2D SC ? Jeg kan ikke finde 4 pts der ikke har respons ?

[Bulder]

Tiden går, klokken slår. Dara mono havde 33% ORR. Teclistamab 73% i RRMM

[Bulder]

Hvad kan det ikke blive til i combo?

[Solsen]

Det var derfor jeg spurgte JW om JNJ ikke have et par duobodies, der kunne tage markedsandele fra dara ...

[Solsen]

Data er i hvert tilfælde gode. Men safety er dara stadig suveræn på.

[Solsen]

Som jeg lige kan se.

[GeorgeBest]

Det kan man frygte - Teclistamab overflødiggør dara, royalty satsen ryger fra 20 til 5%!